Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002032 · ClinicalTrials.gov registry record · NA

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

A NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

Completed
Registry status
NA
Development phase
750
Enrollment target
20
Study locations

NCT00002032 is a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by Pharmacia. The registered enrollment target is 750 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002032, a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by Pharmacia.

COMPLETED
Registry status
NA
Development phase
750 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Interventions

  • DRUG Rifabutin

Study Locations (20)

New York

  • Brooklyn Veterans Administration - Brooklyn
  • Maimonides Med Ctr - Brooklyn
  • Nassau County Med Ctr - East Meadow
  • Long Island Jewish Med Ctr - New Hyde Park
  • Community Research Initiative - New York

Florida

  • Ctr for Special Immunology - Fort Lauderdale
  • TheraFirst Med Ctrs Inc - Fort Lauderdale
  • Mem Hosp Hollywood - Hollywood
  • VP Med Services / HHCS Research Institute Inc - Orlando

Georgia

  • AIDS Research Consortium of Atlanta - Atlanta
  • Grady Memorial Hosp / Hughs Spalding Med Ctr - Atlanta
  • Dr Winkler Weinberg - Roswell

California

  • Ctr for Special Immunology - Irvine
  • Olive View Med Ctr - Sylmar

Missouri

  • Univ of Missouri at Kansas City School of Medicine - Kansas City
  • Research Med Ctr - Kansas City

Colorado

  • Denver Public Health Dept - Denver

District of Columbia

  • Veterans Administration Med Ctr - Washington D.C.

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 750 participants
Phase NA

Sponsor

Pharmacia

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002032

The ClinicalTrials.gov registry entry for NCT00002032 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (69% higher). The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Rifabutin is the first listed.

NCT00002032 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00002032 about?

NCT00002032 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial". The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary o...

What is the current status of trial NCT00002032?

This trial is currently completed. It is a NA study. The enrollment target is 750 participants.

What conditions does trial NCT00002032 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

What interventions are being tested in trial NCT00002032?

The interventions under investigation include: Rifabutin (DRUG).

Who is sponsoring clinical trial NCT00002032?

This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002032 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Mycobacterium Avium-Intracellulare Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.